IGFBPL1

Across TCGA pan-cancer cohorts, IGFBPL1 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of IGFBPL1’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where IGFBPL1 RNA is repressed in tumor relative to normal tissue. In most cancer types IGFBPL1 is over-expressed in tumor, although a few such as THCA and KICH show the opposite, repressed pattern.

THCA, HNSC, and LUAD are the cancer types where IGFBPL1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in IGFBPL1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	All	IV	−4.877	<.001	11	view →
HNSC	All	II,III,IV	+0.406	.002	8	view →
LUAD	Male	All	+1.369	<.001	7	view →
KICH	Female	All	−0.385	<.001	7	view →
BRCA	All	III,IV	+0.770	<.001	6	view →
KIRC	Male	All	−0.218	<.001	5	view →
CHOL	All	All	+1.114	.030	3	view →
LUSC	Female	III,IV	−1.075	.003	2	view →
UCEC	All	All	+0.785	.015	2	view →
LIHC	All	II,III,IV	+0.548	.034	2	view →
READ	Male	All	+0.386	.044	2	view →
BLCA	Male	IV	−1.132	.024	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

IGFBPL1–THCA

Open the THCA breakdown →